{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-036329","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2025-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.665107+00:00","generated_at":"2026-05-16T16:53:52.262359+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Phio completes enrollment in Phase 1b trial of PH-762; positive pathologic responses","bullets":["18 patients treated across 5 dose cohorts; 16 with cSCC, 1 Merkel cell, 1 melanoma.","cSCC responses: 6 complete (100% clearance), 2 near complete (>90%), 2 partial (>50%).","Merkel cell patient had partial response (>50% clearance); no patients showed disease progression.","No dose-limiting toxicities or clinically relevant treatment-emergent adverse effects reported.","Highest dose cohort still enrolling; pathology results expected Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-036329","json":"https://secwatch.observer/filing/0001437749-25-036329.json","markdown":"https://secwatch.observer/filing/0001437749-25-036329.md","text":"https://secwatch.observer/filing/0001437749-25-036329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000143774925036329/0001437749-25-036329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000143774925036329/phio20251121_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T16:53:52.262359+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}